140 related articles for article (PubMed ID: 24003934)
1. Targeting gp130 to prevent inflammation and promote insulin action.
Kraakman MJ; Allen TL; Whitham M; Iliades P; Kammoun HL; Estevez E; Lancaster GI; Febbraio MA
Diabetes Obes Metab; 2013 Sep; 15 Suppl 3():170-5. PubMed ID: 24003934
[TBL] [Abstract][Full Text] [Related]
2. Targeting the glycoprotein 130 receptor subunit to control pain and inflammation.
Jazayeri JA; Upadhyay A; Vernallis AB; Carroll GJ
J Interferon Cytokine Res; 2010 Dec; 30(12):865-73. PubMed ID: 20979530
[TBL] [Abstract][Full Text] [Related]
3. Interleukin-6--a key mediator of systemic and local symptoms in rheumatoid arthritis.
Cronstein BN
Bull NYU Hosp Jt Dis; 2007; 65 Suppl 1():S11-5. PubMed ID: 17708739
[TBL] [Abstract][Full Text] [Related]
4. Interleukin-6: from identification of the cytokine to development of targeted treatments.
Assier E; Boissier MC; Dayer JM
Joint Bone Spine; 2010 Dec; 77(6):532-6. PubMed ID: 20869898
[TBL] [Abstract][Full Text] [Related]
5. Recent advances in the relationship between obesity, inflammation, and insulin resistance.
Bastard JP; Maachi M; Lagathu C; Kim MJ; Caron M; Vidal H; Capeau J; Feve B
Eur Cytokine Netw; 2006 Mar; 17(1):4-12. PubMed ID: 16613757
[TBL] [Abstract][Full Text] [Related]
6. Mesenteric Fat Lipolysis Mediates Obesity-Associated Hepatic Steatosis and Insulin Resistance.
Wueest S; Item F; Lucchini FC; Challa TD; Müller W; Blüher M; Konrad D
Diabetes; 2016 Jan; 65(1):140-8. PubMed ID: 26384383
[TBL] [Abstract][Full Text] [Related]
7. Blocking IL-6 trans-signaling prevents high-fat diet-induced adipose tissue macrophage recruitment but does not improve insulin resistance.
Kraakman MJ; Kammoun HL; Allen TL; Deswaerte V; Henstridge DC; Estevez E; Matthews VB; Neill B; White DA; Murphy AJ; Peijs L; Yang C; Risis S; Bruce CR; Du XJ; Bobik A; Lee-Young RS; Kingwell BA; Vasanthakumar A; Shi W; Kallies A; Lancaster GI; Rose-John S; Febbraio MA
Cell Metab; 2015 Mar; 21(3):403-16. PubMed ID: 25738456
[TBL] [Abstract][Full Text] [Related]
8. Interleukin-6 trans-signalling in chronic inflammation and cancer.
Scheller J; Ohnesorge N; Rose-John S
Scand J Immunol; 2006 May; 63(5):321-9. PubMed ID: 16640655
[TBL] [Abstract][Full Text] [Related]
9. Targeting Interleukin-6 Signaling in Clinic.
Kang S; Tanaka T; Narazaki M; Kishimoto T
Immunity; 2019 Apr; 50(4):1007-1023. PubMed ID: 30995492
[TBL] [Abstract][Full Text] [Related]
10. Interleukin-6 and insulin resistance.
Kim JH; Bachmann RA; Chen J
Vitam Horm; 2009; 80():613-33. PubMed ID: 19251052
[TBL] [Abstract][Full Text] [Related]
11. Interleukin-6 biology is coordinated by membrane-bound and soluble receptors: role in inflammation and cancer.
Rose-John S; Scheller J; Elson G; Jones SA
J Leukoc Biol; 2006 Aug; 80(2):227-36. PubMed ID: 16707558
[TBL] [Abstract][Full Text] [Related]
12. [Obesity, inflammation and insulin resistance: role of gp 130 receptor ligands].
Marcos-Gómez B; Bustos M; Prieto J; Martínez JA; Moreno-Aliaga MJ
An Sist Sanit Navar; 2008; 31(2):113-23. PubMed ID: 18953360
[TBL] [Abstract][Full Text] [Related]
13. Inhibition of interleukin-6-transsignaling via gp130-Fc in hemorrhagic shock and sepsis.
Mees ST; Toellner S; Marx K; Faendrich F; Kallen KJ; Schroeder J; Haier J; Kahlke V
J Surg Res; 2009 Dec; 157(2):235-42. PubMed ID: 19589542
[TBL] [Abstract][Full Text] [Related]
14. The biology and medical implications of interleukin-6.
Tanaka T; Kishimoto T
Cancer Immunol Res; 2014 Apr; 2(4):288-94. PubMed ID: 24764575
[TBL] [Abstract][Full Text] [Related]
15. Humanized antihuman IL-6 receptor antibody, tocilizumab.
Nishimoto N; Kishimoto T
Handb Exp Pharmacol; 2008; (181):151-60. PubMed ID: 18071945
[TBL] [Abstract][Full Text] [Related]
16. Interleukin-6 as a key player in systemic inflammation and joint destruction.
Fonseca JE; Santos MJ; Canhão H; Choy E
Autoimmun Rev; 2009 Jun; 8(7):538-42. PubMed ID: 19189867
[TBL] [Abstract][Full Text] [Related]
17. Molecular and cellular mechanisms linking inflammation to insulin resistance and β-cell dysfunction.
Khodabandehloo H; Gorgani-Firuzjaee S; Panahi G; Meshkani R
Transl Res; 2016 Jan; 167(1):228-56. PubMed ID: 26408801
[TBL] [Abstract][Full Text] [Related]
18. Interleukin-6 depletion selectively improves hepatic insulin action in obesity.
Klover PJ; Clementi AH; Mooney RA
Endocrinology; 2005 Aug; 146(8):3417-27. PubMed ID: 15845623
[TBL] [Abstract][Full Text] [Related]
19. Discovery and characterization of olokizumab: a humanized antibody targeting interleukin-6 and neutralizing gp130-signaling.
Shaw S; Bourne T; Meier C; Carrington B; Gelinas R; Henry A; Popplewell A; Adams R; Baker T; Rapecki S; Marshall D; Moore A; Neale H; Lawson A
MAbs; 2014; 6(3):774-82. PubMed ID: 24670876
[TBL] [Abstract][Full Text] [Related]
20. Interleukin-6 and its receptors: a highly regulated and dynamic system.
Wolf J; Rose-John S; Garbers C
Cytokine; 2014 Nov; 70(1):11-20. PubMed ID: 24986424
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
